Expanded antigen-specific donor regulatory T cells for GVHD prevention.

BloodSep 24, 2026
Clinical ResearchHematologyOncology (Medical)

Joseph Pidala, Nicoletta Cieri, Michael J Schell et al.

✦ AI-curated · Sources linked

In 30 seconds

This phase 1 clinical trial evaluated the safety and preliminary efficacy of expanded minor histocompatibility antigen (mHAg)-specific donor regulatory T cells (Treg) for preventing graft-versus-host disease (GVHD) in 15 patients undergoing allogeneic hematopoietic cell transplantation. The maximum tolerated dose was determined to be 4 × 10^5/kg, with a day 100 cumulative incidence of grade II to IV acute GVHD at 13%.

Key findings

  • No dose-limiting toxicities were observed across all dose levels.
  • The day 100 cumulative incidence of grade II to IV acute GVHD was 13%.
  • Moderate/severe chronic GVHD rates were 6.7% at 1 year and 20% at 3 years.
  • Overall survival at the median follow-up of 41.7 months was 73%.

Why it matters

The findings suggest that mHAg-specific expanded donor Treg may provide a safe and effective strategy for GVHD prevention, potentially improving outcomes in patients undergoing allogeneic hematopoietic cell transplantation.

Source

PubMed · PMID 42322116

Published in Blood. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Hematology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.